제넥신

095700KOSDAQ자연과학 및 공학 연구개발업

58.3 / 100

Reference Date: 2026-07-24

Financial Score25.5 / 40

News Sentiment18.8 / 25

Momentum4.0 / 20

Disclosure10.0 / 15

AI Analysis: PBR is significantly undervalued vs. peers but ROE is below the industry average. Slightly down 4.7% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

Genexine focuses on developing innovative therapies for cancer and immune-related diseases using its proprietary bioPROTAC technology, which leverages biologics like nanobodies to overcome limitations of traditional small-molecule-based PROTAC approaches. The company aims to effectively degrade target proteins by utilizing advanced targeted protein degradation techniques, enabling precise and efficient disease treatment.

Number of Employees

68people

Average Salary

82.7M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 43.644.0Point

PBR

0.45Industry Average 2.527.0Point

Half of industry avg (excellent)

ROE

-10.71Industry Average -32.093.5Point

Well below industry avg

Debt Ratio

3.10Industry Average 7.316.5Point

Half of industry avg (excellent)

Trend 2023~20254.5 / 10 points

Revenue Growth Rate

2.5 / 3

Avg ▲11.1% (2-year basis)

Operating Profit Growth Rate

2.0 / 3

Avg ▲6.3% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -18.9% (improving, 3yr)

Detailed News Sentiment

2 totalPositive 1Neutral 0Negative 1Average Sentiment Score 75

Positive
“내년까지 후보물질 기술수출…바이오프로탁 글로벌 리더 될 것”
제넥신의 대표가 바이오프로탁 기술의 해외 기술수출 계획을 발표하며 글로벌 리더십 확보를 강조.
Negative
HLB·제넥신도 발목 잡혔다…효능·안전성 입증해도 신약 허가 가르는.....
미국 FDA의 보완 요구로 인해 제넥신의 신약 허가 과정이 지연되고 추가 비용 부담이 증가하고 있다.

Detailed Momentum

52-week position1.0Point

Near 52w low (4%, downtrend)

Current 2,430Won52-week high 7,10052-week low 2,195

1-month return2.0Point

1m -4.71% (slight drop)

Volume trend1.0Point

Volume decreasing

Detailed Disclosure

2 totalPositive 0Neutral 2Negative 0

Neutral타인에대한담보제공결정2026-07-03
Neutral[기재정정]타인에대한담보제공결정2026-07-03